Search

Your search keyword '"Saori Nishio"' showing total 100 results

Search Constraints

Start Over You searched for: Author "Saori Nishio" Remove constraint Author: "Saori Nishio"
100 results on '"Saori Nishio"'

Search Results

1. Effects of canagliflozin on brain natriuretic peptide levels in patients with type 2 diabetes on peritoneal dialysis in Japan: protocol for a multicentre, prospective, randomised controlled trial (CARD-PD trial)

2. Inhibition of Toll-like receptor 4 and Interleukin-1 receptor prevent SARS-CoV-2 mediated kidney injury

3. Characterization of cytoskeletal and structural effects of INF2 variants causing glomerulopathy and neuropathy

4. Imbalanced expression of cation-chloride cotransporters as a potential therapeutic target in an Angelman syndrome mouse model

5. Transcriptional dynamics of granulocytes in direct response to incubation with SARS‐CoV‐2

6. CD47 blockade ameliorates autoimmune vasculitis via efferocytosis of neutrophil extracellular traps

7. Predictors of early remission of proteinuria in adult patients with minimal change disease: a retrospective cohort study

8. Soluble Interleukin-2 Receptor Predicts Treatment Outcome in Patients With Autoimmune Tubulointerstitial Nephritis. A Preliminary Study

9. Monkeys mutant for PKD1 recapitulate human autosomal dominant polycystic kidney disease

10. The Pathogenicity of BPI-ANCA in a Patient With Systemic Vasculitis

11. Deep learning analysis of clinical course of primary nephrotic syndrome: Japan Nephrotic Syndrome Cohort Study (JNSCS)

13. Development of ANCA-associated vasculitis followed by SARS-CoV-2 vaccination in a patient with HLA-DRB1*09:01 allele

14. A Case of COVID-19 Successfully Treated with Minocycline and Saiko-Keishi-To

15. Bucillamine use for rheumatoid arthritis and type 2 diabetes mellitus are associated with neural epidermal growth factor-like 1 (NELL1)-associated membranous nephropathy

16. Knowledge of Chronic Kidney Disease among the General Population: A Questionnaire Survey in Hokkaido Prefecture, Japan

17. Factors predicting decline in renal function and kidney volume growth in autosomal dominant polycystic kidney disease: a prospective cohort study (Japanese Polycystic Kidney Disease registry: J-PKD)

18. Acute Kidney Injury and Remission of Proteinuria in Minimal Change Disease

19. Regulation of NETosis and Inflammation by Cyclophilin D in Myeloperoxidase-Positive Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

21. Incidence of remission and relapse of proteinuria, end-stage kidney disease, mortality, and major outcomes in primary nephrotic syndrome: the Japan Nephrotic Syndrome Cohort Study (JNSCS)

22. Cystic Kidney Diseases That Require a Differential Diagnosis from Autosomal Dominant Polycystic Kidney Disease (ADPKD)

23. Time to remission of proteinuria and incidence of relapse in patients with steroid-sensitive minimal change disease and focal segmental glomerulosclerosis: the Japan Nephrotic Syndrome Cohort Study

24. The relationship between liver cyst volume and QOL in Japanese ADPKD patients

25. A digest from evidence-based Clinical Practice Guideline for Polycystic Kidney Disease 2020

28. Better remission rates in elderly Japanese patients with primary membranous nephropathy in nationwide real-world practice: The Japan Nephrotic Syndrome Cohort Study (JNSCS)

29. Regional variations in immunosuppressive therapy in patients with primary nephrotic syndrome: the Japan nephrotic syndrome cohort study

31. Interferon-inducible Mx1 protein is highly expressed in renal tissues from treatment-naïve lupus nephritis, but not in those under immunosuppressive treatment

32. Recombinant thrombomodulin ameliorates autoimmune vasculitis via immune response regulation and tissue injury protection

33. Increased urinary exosomal SYT17 levels in chronic active antibody-mediated rejection after kidney transplantation via the IL-6 amplifier

34. The Pathogenicity of BPI-ANCA in a Patient With Systemic Vasculitis

35. SaO001THE EFFECT OF L-TYPE AMINO ACID TRANSPORTER 1 IN THE CYST FORMATION OF MODEL MICE FOR POLYCYSTIC KIDNEY DISEASE

36. FP453WEEKLY TERIPARATIDE AGENT POTENTIATES BONE MINERAL TURN OVER IN HEMODIALYSIS PATIENTS WITH LOW PARATHYROID HORMONE (PTH) LEVELS: A PROSPECTIVE STUDY

37. SP004LONG-TERM TREATMENT OF TOLVAPTAN FOR AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE: A SINGLE CENTRE RETROSPECTIVE COHORT STUDY

38. FP125A ROLE OF SOLUBLE INTERLEUKIN-2 RECEPTOR LEVELS IN THE PREDICTION OF STEROID RESPONSE IN PATIENTS WITH TUBULOINTERSTITIAL NEPHRITIS

39. Impact of Weekly Teriparatide on the Bone and Mineral Metabolism in Hemodialysis Patients With Relatively Low Serum Parathyroid Hormone: A Pilot Study

40. A case report dysregulated neutrophil extracellular traps in a patient with propylthiouracil-induced anti-neutrophil cytoplasmic antibody-associated vasculitis

41. 018. ANTI-NEUTROPHIL EXTRACELLULAR TRAP ANTIBODY IN PATIENTS WITH MICROSCOPIC POLYANGIITIS

42. COVID-19 Treated with Minocycline and Saiko-keishi-to: A Case Report.

43. Evidence-based clinical practice guidelines for polycystic kidney disease 2014

44. The responses of macrophages in interaction with neutrophils that undergo NETosis

45. The presence of anti-neutrophil extracellular trap antibody in patients with microscopic polyangiitis

46. Initial experience with the use of tris-acryl gelatin microspheres for transcatheter arterial embolization for enlarged polycystic liver

49. Monkeys mutant for PKD1 recapitulate human autosomal dominant polycystic kidney disease

50. The first pure form of Ostertag-type amyloidosis in Japan: a sporadic case of hereditary fibrinogen Aα-chain amyloidosis associated with a novel frameshift variant

Catalog

Books, media, physical & digital resources